M&G Investments Boosts bit.bio with Significant Funding Round
M&G Investments has taken a bold step in supporting innovation in drug discovery by leading a pivotal $50 million Series C funding round for bit.bio. This Cambridge-based biotech company is at the forefront of creating next-generation programming technology for human cells. The decision to invest in bit.bio highlights M&G's confidence in the potential for technological advancements in the UK, especially in the realm of drug development.
Accelerating Innovation in Drug Development
The funding from M&G will enable bit.bio to enhance its capabilities in developing and distributing its innovative products. With plans to extend its operations to a global scale, the company aims to penetrate the lucrative toxicology market while reinforcing its manufacturing and generating comprehensive datasets to train artificial intelligence models.
bit.bio's specialized ioCells™ human cell products are utilized by various leading pharmaceutical companies and academic institutions across the globe. By providing human cells and models for crucial areas such as research and drug discovery, the company is driving the shift towards advanced human-relevant methodologies. These New Approach Methodologies (NAMs) embrace cell-based and computational models, presenting a more predictive pathway for medicine development compared to traditional animal testing practices.
M&G's Commitment to Future Growth
Investing through its Crossover strategy, M&G is utilizing its public equity business to back bit.bio, which is part of M&G Life's substantial £130 billion With Profits Fund. This strategy focuses on nurturing high-quality and fast-growing private companies, facilitating their eventual transition into public markets.
In a significant addition to its leadership, bit.bio has welcomed Lord David Prior as an independent director and Chair of the Board. With over two decades of distinguished leadership in UK life sciences and health policy, Lord Prior’s expertise will guide the company's direction.
Quotes from Leadership
Przemek Obloj, Chief Executive of bit.bio, emphasized the company’s mission: "By providing reliable human cells for research and safety testing, we're helping to accelerate drug development. Our technology is designed to decrease reliance on animal testing while enhancing the accuracy and relevance of preclinical research. This new funding allows us to speed up development across various stages toward more robust safety testing models."
Cornel Chiriac, Investment Director at M&G, also shared insights on the investment: "This substantial funding for bit.bio signifies our commitment to support innovative businesses in the UK. The company’s advancements in cell programming position it uniquely in a rapidly evolving environment. As a long-term investor, we aim to nurture the innovation necessary for economic progress while enhancing Britain's standing in the global market. Bit.bio is truly a beacon of success poised for considerable international growth."
Vision for the Future
According to Lord David Prior, bit.bio's technology is exceptional, and he anticipates that the company will successfully transform this advantage into consistent commercial success. His support and vision will be critical as bit.bio expands its influence within pharmaceutical and research organizations worldwide.
Understanding New Approach Methodologies
The investment serves as a reminder of the emerging era of New Approach Methodologies (NAMs) in drug discovery and development. NAMs leverage innovative scientific techniques that prioritize human relevance, forgoing traditional animal testing in favor of advanced methods such as cell-based assays and organ-on-a-chip systems, thus fostering more ethical and regulatory-compatible solutions.
About M&G Investments
M&G Investments holds the status of a key player in the realm of asset management. With assets amounting to £365 billion, the firm operates across various regions, offering diverse investment solutions tailored for individual savers and institutional investors alike. With a strong commitment to responsible investing and a focus on achieving net-zero emissions by 2050, M&G demonstrates leadership in building sustainable investment practices.
About bit.bio
Since its inception as a spin-off from the University of Cambridge in 2016, bit.bio has secured over $200 million from prominent investors across the industry. It prides itself on creating functional, human-relevant cell types at scale, further bolstered by its AI-driven discovery platform. With a diverse portfolio exceeding 50 different ioCells products, bit.bio stands as a pivotal contributor to the future landscape of life sciences.
Frequently Asked Questions
What is the significance of M&G's investment in bit.bio?
M&G's investment signifies a major endorsement of bit.bio's innovative cell programming technology and reflects confidence in the future of drug development in the UK.
How will the funding impact bit.bio's operations?
The funding will enhance bit.bio's ability to scale globally, expand product access, and enter the toxicology market while contributing to industry-driven datasets for AI model training.
What are New Approach Methodologies (NAMs)?
NAMs are innovative scientific methods aimed at drug discovery and testing that avoid traditional animal testing, promoting ethical and regulatory best practices.
Who is Lord David Prior and what role will he play at bit.bio?
Lord David Prior is a seasoned leader in UK life sciences. He will serve as an independent director and Board Chair, guiding bit.bio in its strategic growth and development.
Why is responsible investing important for M&G Investments?
Responsible investing is crucial for M&G as it pursues positive impact and strives for sustainability, aiming for net-zero emissions across its investment portfolio by 2050.
